-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Current available therapies and future directions in the treatment of malignant gliomas
Review
(3045) Views (640) Full article downloads
Authors: Annick Desjardins, David A Reardon, James J Vredenburgh
Published Date December 2008
Volume 2009:3 Pages 15 - 25
DOI: http://dx.doi.org/10.2147/BTT.S3098
Annick Desjardins1,2, David A Reardon1,3, James J Vredenburgh1,2
1The Preston Robert Tisch Brain Tumor Center; 2Department of Medicine; 3Department of Surgery, Duke University Medical Center, Durham, NC, USA
Abstract: The prognosis of patients diagnosed with malignant glioma (MG) remains poor. However, recent advances in neuro-oncology allowing a better understanding of this particular disease have allowed the development of new therapeutics. Many molecular genetic and signal transduction pathway targets have been identified that are now being investigated. Novel locoregional treatments, as well as strategies to improve regional delivery, are being evaluated. Studies of combinations of these approaches are also underway. In this review, we will discuss the current and future therapies under evaluation for the treatment of malignant gliomas.
Keywords: glioma, glioblastoma, targeted therapy, kinase inhibitor
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




